drugset / Trial / NCT04690322
POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, randomized control trial in which each patient will be randomly assigned to receive either extended half-life factor VIII based replacement therapy or non-FVIII based replacement therapy, which are both standard of care treatment for persons with Hemophilia A.
Timeline
- Start
- 2021-04-15
- Primary completion
- 2027-07
- Completion
- 2027-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ANTIHEMOPHILIC FACTOR, PEGYLATED (MW 20000) HUMAN SEQUENCE RECOMBINANT | Protein / enzyme biologic | — | — |
| Comparator | Efmoroctocog Alfa | Protein / enzyme biologic | — | — |
| Comparator | Emicizumab | Monoclonal antibody | — | — |